Research ExplorerPublicationsSubjective and objective prospective, long-term analysis of ...

Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy

Standard

Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. / Heinzer, H; Mir, T S; Huland, E; Huland, H.

In: J CLIN ONCOL, Vol. 17, No. 11, 11.1999, p. 3612-3620.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heinzer, H, Mir, TS, Huland, E & Huland, H 1999, 'Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy', J CLIN ONCOL, vol. 17, no. 11, pp. 3612-3620. https://doi.org/10.1200/JCO.1999.17.11.3612

APA

Heinzer, H., Mir, T. S., Huland, E., & Huland, H. (1999). Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J CLIN ONCOL, 17(11), 3612-3620. https://doi.org/10.1200/JCO.1999.17.11.3612

Vancouver

Heinzer H, Mir TS, Huland E, Huland H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J CLIN ONCOL. 1999 Nov;17(11):3612-3620. https://doi.org/10.1200/JCO.1999.17.11.3612

Bibtex

@article{eba7bdf1f71c41be84b07acbbce2639a,
title = "Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy",
abstract = "PURPOSE: We conducted both a subjective and objective, prospective quality-of-life analysis during high-dose (36 x 10(6) immunizing units/d) inhalational interleukin (IL)-2 treatment (mean treatment time, 13.4 months) of 15 patients with metastatic renal cell carcinoma (mRCC). Additionally, quality of life for 10 patients with mRCC receiving low-dose (9 x 10(6) IU/m(2)/d for 5 days) intravenous IL-2 treatment also was evaluated.PATIENTS AND METHODS: Patients responded to the European Organization for Research and Treatment of Cancer quality-of-life questionnaire QLQ-C30 before and during inhalational IL-2 treatment at 1, 3, 6, 9, and 12 months and before and once during intravenous IL-2 treatment. A clinician assessed patient well-being using the Quality of Well-Being scale to calculate once weekly quality-adjusted life-years (QALYs) during inhalational IL-2 treatment.RESULTS: Patients completed 103 questionnaires and clinicians performed 892 QALY calculations. For patients treated with inhalational IL-2, the mean quality-of-life score deteriorated modestly but significantly 1 month after treatment initiation (15.1%, P =.01) but did not differ significantly from pretreatment scores after 3, 6, 9, and 12 months of treatment. Inhalational IL-2 therapy stabilized patient quality of life for a mean of 13.4 months. The resulting QALY calculation for patients on inhalation IL-2 was 70.1% of 13.4 months, representing 9.4 months of QALY. In comparison, patients who received intravenous IL-2 showed a more marked, statistically significant deterioration in mean quality-of-life score during treatment (27%, P =.006); moreover, three of these 10 patients experienced treatment-related toxicity that prevented questionnaire completion.CONCLUSION: Quality-of-life analysis during immunotherapy provides valuable information regarding cancer treatment outcomes.",
keywords = "Activities of Daily Living, Administration, Inhalation, Adult, Carcinoma, Renal Cell/drug therapy, Combined Modality Therapy, Dose-Response Relationship, Drug, Female, Humans, Interleukin-2/administration & dosage, Kidney Neoplasms/drug therapy, Male, Middle Aged, Prospective Studies, Quality-Adjusted Life Years, Surveys and Questionnaires",
author = "H Heinzer and Mir, {T S} and E Huland and H Huland",
year = "1999",
month = nov,
doi = "10.1200/JCO.1999.17.11.3612",
language = "English",
volume = "17",
pages = "3612--3620",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

RIS

TY - JOUR

T1 - Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy

AU - Heinzer, H

AU - Mir, T S

AU - Huland, E

AU - Huland, H

PY - 1999/11

Y1 - 1999/11

N2 - PURPOSE: We conducted both a subjective and objective, prospective quality-of-life analysis during high-dose (36 x 10(6) immunizing units/d) inhalational interleukin (IL)-2 treatment (mean treatment time, 13.4 months) of 15 patients with metastatic renal cell carcinoma (mRCC). Additionally, quality of life for 10 patients with mRCC receiving low-dose (9 x 10(6) IU/m(2)/d for 5 days) intravenous IL-2 treatment also was evaluated.PATIENTS AND METHODS: Patients responded to the European Organization for Research and Treatment of Cancer quality-of-life questionnaire QLQ-C30 before and during inhalational IL-2 treatment at 1, 3, 6, 9, and 12 months and before and once during intravenous IL-2 treatment. A clinician assessed patient well-being using the Quality of Well-Being scale to calculate once weekly quality-adjusted life-years (QALYs) during inhalational IL-2 treatment.RESULTS: Patients completed 103 questionnaires and clinicians performed 892 QALY calculations. For patients treated with inhalational IL-2, the mean quality-of-life score deteriorated modestly but significantly 1 month after treatment initiation (15.1%, P =.01) but did not differ significantly from pretreatment scores after 3, 6, 9, and 12 months of treatment. Inhalational IL-2 therapy stabilized patient quality of life for a mean of 13.4 months. The resulting QALY calculation for patients on inhalation IL-2 was 70.1% of 13.4 months, representing 9.4 months of QALY. In comparison, patients who received intravenous IL-2 showed a more marked, statistically significant deterioration in mean quality-of-life score during treatment (27%, P =.006); moreover, three of these 10 patients experienced treatment-related toxicity that prevented questionnaire completion.CONCLUSION: Quality-of-life analysis during immunotherapy provides valuable information regarding cancer treatment outcomes.

AB - PURPOSE: We conducted both a subjective and objective, prospective quality-of-life analysis during high-dose (36 x 10(6) immunizing units/d) inhalational interleukin (IL)-2 treatment (mean treatment time, 13.4 months) of 15 patients with metastatic renal cell carcinoma (mRCC). Additionally, quality of life for 10 patients with mRCC receiving low-dose (9 x 10(6) IU/m(2)/d for 5 days) intravenous IL-2 treatment also was evaluated.PATIENTS AND METHODS: Patients responded to the European Organization for Research and Treatment of Cancer quality-of-life questionnaire QLQ-C30 before and during inhalational IL-2 treatment at 1, 3, 6, 9, and 12 months and before and once during intravenous IL-2 treatment. A clinician assessed patient well-being using the Quality of Well-Being scale to calculate once weekly quality-adjusted life-years (QALYs) during inhalational IL-2 treatment.RESULTS: Patients completed 103 questionnaires and clinicians performed 892 QALY calculations. For patients treated with inhalational IL-2, the mean quality-of-life score deteriorated modestly but significantly 1 month after treatment initiation (15.1%, P =.01) but did not differ significantly from pretreatment scores after 3, 6, 9, and 12 months of treatment. Inhalational IL-2 therapy stabilized patient quality of life for a mean of 13.4 months. The resulting QALY calculation for patients on inhalation IL-2 was 70.1% of 13.4 months, representing 9.4 months of QALY. In comparison, patients who received intravenous IL-2 showed a more marked, statistically significant deterioration in mean quality-of-life score during treatment (27%, P =.006); moreover, three of these 10 patients experienced treatment-related toxicity that prevented questionnaire completion.CONCLUSION: Quality-of-life analysis during immunotherapy provides valuable information regarding cancer treatment outcomes.

KW - Activities of Daily Living

KW - Administration, Inhalation

KW - Adult

KW - Carcinoma, Renal Cell/drug therapy

KW - Combined Modality Therapy

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Interleukin-2/administration & dosage

KW - Kidney Neoplasms/drug therapy

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Quality-Adjusted Life Years

KW - Surveys and Questionnaires

U2 - 10.1200/JCO.1999.17.11.3612

DO - 10.1200/JCO.1999.17.11.3612

M3 - SCORING: Journal article

C2 - 10550161

VL - 17

SP - 3612

EP - 3620

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 11

ER -